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PAI-1. FDR was positively correlated with serum albumin.Postischemic vasodilation, endothelial activation, and cardio-
FDR and time to FDR were negatively correlated with CCAvascular remodeling in end-stage renal disease.
IMT and LV mass. CCA distensibility was positively associatedBackground. Cardiovascular complications are the major
with FDR (P , 0.001) and negatively with time to FDR (P ,cause of death in end-stage renal disease (ESRD) patients.
0.001). The PAI-1 concentration was positively correlated withThese complications are associated with concomitant cardiac
and vascular remodeling, including left ventricular (LV) hyper- CCA IMT (P , 0.01) and negatively with CCA distensibility
trophy and hypertrophy of arterial walls. The endothelium (P , 0.001).
influences the process of arterial remodeling. ESRD patients Conclusions. Our data provide the first evidence that cardiac
are characterized by the development of both cardiovascular and arterial remodeling in ESRD patients are inversely related
remodeling and endothelial dysfunction. to forearm reactive hyperemia. The diminished hyperemic re-
Methods. Common carotid artery (CCA) intima-media thick- sponse is due to the shorter duration of hyperemia and is
ness (IMT), CCA diameter, CCA distensibility, LV mass, and associated with higher concentrations of serum markers of
function were determined in 60 stable ESRD patients on hemo- endothelial activation, suggesting that, in ESRD patients, endo-
dialysis and 34 age-, sex-, and blood pressure (BP)-matched thelial dysfunction may be a factor influencing cardiovascular
controls, and their relationships with endothelial alterations changes.
were estimated by forearm postischemic vasodilation [flow debt
repayment (FDR)] measured by venous plethysmography. We
also evaluated the relationships between FDR and several car-
Cardiovascular complications are the major cause ofdiovascular risk factors or markers of inflammatory response
or endothelial activation, for example, duration of dialysis, death and morbidity of end-stage renal disease (ESRD)
BP, smoking habits, cholesterol, parathormone (PTH), serum patients [1]. These complications are associated with car-
albumin, plasma fibrinogen, C-reactive protein (CRP), plasma diovascular remodeling characterized by left ventricularhomocysteine, plasminogen activator inhibitor (PAI-1), and
(LV) hypertrophy, dilation, and hypertrophy of large con-von Willebrand factor (vWF).
duit arteries, and occlusive atherosclerotic lesions [2–6].Results. ESRD patients had increased LV mass, CCA diam-
eter and CCA IMT, and had decreased CCA distensibility (P , Structural alterations of the cardiovascular system are
0.05). While the postischemic peak flow was comparable in the consequence of metabolic disturbances and long-
controls and ESRD patients (29.2 6 9.1 vs. 27.9 6 0.2 mL/100
term pressure and/or flow overload characteristic of themL/min), FDR was lower in ESRD patients (116 6 31 vs. 88 6
uremic state. These structural remodelings result in sev-32%, P , 0.001) because of the shorter duration of vasodilation
(127 6 36 vs. 96 6 32 s, P , 0.001). The time to complete eral functional abnormalities, mainly stiffening of the
FDR was longer in ESRD patients (110 6 54 vs. 162 6 72 s, heart and vessels [2–4, 6]. As shown experimentally,
P , 0.001). ESRD patients had lower high-density lipoprotein the endothelium influences the geometric and structuralcholesterol and serum albumin (P , 0.01) and higher triglycer-
properties of large conduit arteries, and alterations ofides, fibrinogen, plasma homocysteine, vWF (P , 0.01), and
endothelial function might be associated with arterialPAI-1 (P , 0.05). For ESRD patients, significant negative
age- and pressure-independent correlations were established remodeling [7, 8]. Endothelial function is altered in
between FDR and CCA diameter, duration of dialysis, and ESRD patients, as shown by decreased vasodilator re-
sponses of macrocirculations and microcirculations to
various stimuli, including ischemia, hyperthermia, or ace-Key words: cardiac hypertrophy, arteriosclerosis, endothelium, renal
failure, hyperemia, uremia. tylcholine [9–14]. The present study was designed to
analyze in ESRD patients the relationships between arte-
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METHODS Millar strain-gauge transducer (SPT-301; Millar Instru-
ments, Houston, TX, USA). CCA pulse pressure ampli-Subjects
tude (DP) was analyzed by applanation tonometry using
Sixty stable, nondiabetic, ESRD patients on hemodial- a sphygmocardiograph (PWV Medical, Sydney, NSW,
ysis for 103 6 187 months (range 8 to 302 months) were Australia) and a generalized transfer function. A de-
included. Thirty-four age-, sex-and blood pressure (BP)- tailed description of this system was published elsewhere
matched nonuremic subjects served as the control group. [3, 17]. The CCA diameter was measured with a high-
On the basis of a clinical work-up and complementary resolution B-mode (7.5 MHz transducer) echotracking
paraclinical investigations (echocardiography, EKG, echo- system (Wall-Track System; Pie Medical, Maastricht,
Doppler examination), patients or controls with acute The Netherlands). A complete detailed description of
myocardial infarction, valvular heart disease, cerebral this system and the reproducibility of the measurements
vascular disease, common carotid artery (CCA) stenosis, were published previously [3, 18]. For CCA diameter,
or heart failure were excluded. Fifty ESRD patients were the accuracy is 630 mm, and the repeatability coefficient
regularly receiving recombinant human erythropoietin. of the measurements was 60.273 mm. Measurements
Twenty-five ESRD patients and 16 controls were taking were made on the CCA on the side opposite to the
an antihypertensive drug, which was stopped four weeks arteriovenous shunt, 2 cm below the bifurcation. CCA
prior to the study. Patients were dialyzed with an AN69 intima-media thickness (IMT) was measured on the far
membrane (Hospal, Meyzieu, France) and a bicarbonate wall at the same level as the diameter measurements with
dialysate. The duration of dialysis was individually tai- computer-assisted acquisition, processing, and storage.
lored (4 to 6 hours three times per week) to control body The computing equipment was linked to an 80386/16
fluids and blood chemistry and to achieve a Kt/V .1.2 MHz processor and an imaging card providing real-time
(1.48 6 0.14). Investigations were performed in the digitizing of the video analog signal from the echorecord-
morning before the midweek hemodialysis session. Each ing (processing corresponding to 256 levels of gray). The
subject gave informed written consent to participate in IMT was automatically analyzed from changes of density
the study, which was approved by our institutional review of the section perpendicular to the vessel wall with dedi-
board. cated software (Eurequa, TSA, Meudon, France) [19].
The repeatability of the IMT measurement was 660 mmCardiac measurements
[3, 4]. CCA distensibility was determined from changes
Echocardiographic studies were performed using a of the CCA diameter during systole (Ds-Dd; where Ds
Hewlett-Packard Sonos 100 device equipped with a 2.25 is the CCA end-systolic diameter and Dd is CCA end-
MHz probe, allowing M-mode, two-dimensional, and diastolic diameter) and simultaneously measured DP ac-
pulsed Doppler measurements. Measurements were per- cording to the formula: CCA distensibility 5 2[(Ds 2 d)/
formed blindly by two physicians according to the recom- Dd]/DP (kPa21 · 1023) [3, 18]. The repeatability coeffi-
mendations of the American Society of Echocardiography cient was 61 kPa21 · 1023.
[15]. Interobserver and intraobserver reproducibilities
Forearm reactive hyperemiawere reported previously [3]. M-mode measurements
included LV posterior wall thickness, interventricular Forearm blood flow (FBF in mL/100 mL/min) was
septal thickness, and LV end-diastolic diameter. LV mass measured by venous occlusion plethysmography on the
was calculated according to the Penn convention [16]. forearm contralateral to the arteriovenous shunt in dial-
Stroke volume was calculated from the LV outflow ve- ysis patients (Perivein, Janssens, Belgium). The forearm
locity integral (cm/beat, that is, stroke distance) and aor- was placed in adduction 10 cm above the heart level. A
tic outflow diameter, and cardiac output (CO) was calcu- pneumatic venous occlusion cuff was placed around the
lated as the product of stroke volume 3 heart rate. CO upper arm and connected to an automatic inflator. A
was expressed in mL/min/100 g body wt. LV outflow and mercury strain gauge was placed on the largest part of the
aortic velocities were taken from the apical position. arm distal to the humeral epicondyle. After calibration,
venous occlusion was achieved by cuff inflation to 50
Common carotid artery measurements mm Hg over two seconds for the measurement of base-
Brachial BP was measured with a mercury sphygmo- line blood flow. The reactive hyperemic response in the
manometer after 15 minutes of recumbency. Phases I forearm was assessed using a standardized protocol
and V of the Korotkoff sounds were taken as the systolic (Fig. 1) [12, 20]. In addition to the previously described
BP (SBP) and diastolic BP (DBP) and the mean BP apparatus, a second pneumatic cuff (arterial occlusion
(MBP) as MBP 5 DBP 1 (SBP 2 DBP/3). Five mea- cuff) was placed on the arm proximal to the venous
surements taken at two-minute intervals were averaged. occlusion cuff and the gauge. After control flow measure-
The CCA pressure wave was recorded noninvasively ments were obtained, the arterial occlusion cuff was in-
flated to 300 mm Hg for a period of five minutes. Tenwith a pencil-type probe incorporating a high-fidelity
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Fig. 1. Schematic representation of a reactive
hyperemic response in the human forearm
after five minutes of ischemia [12]. FDR (%)
is the ratio between excess hyperemic flow (B,
defined as the area under the curve between
the release of ischemia and duration of hyper-
emia) and the flow debt (A, the area under the
curve between the start and end of ischemic
period).
seconds before deflating the arterial cuff, the venous metric high-performance liquid chromatography method
as previously reported [21]. Parathormone (PTH) con-occlusion cuff was inflated to 50 mm Hg. At time “zero,”
centrations were determined using a specific radioimmu-the arterial cuff was deflated, and the FBF was measured.
noassay. Plasminogen activator inhibitor-1 (PAI-1) andFBF was then measured every 15 seconds until resting
von Willebrand factor (vWF) levels were measured inflow levels were reached, and then every minute until a
43 ESRD patients and 34 controls with an enzyme-linkedtotal postischemic period of 5 minutes had elapsed. The
immunosorbent assay (ELISA) kit purchased from Diag-following parameters were determined (Fig. 1): the flow
nostica Stago (Asnie`res, France). All of these assays weredebt (A, that is, the area under the curve between the
calibrated using reference plasmas, and purified stan-start and end of ischemic period), the postischemic peak
dards were provided by the manufacturers.flow (in mL/100 mL/min and as percentage of baseline),
the duration of the hyperemic response(s), the excess
Statistical analyseshyperemic flow (B, defined as the area under the curve
Data are expressed as means 6 SD. Student’s t-testbetween the release of ischemia and duration of hyper-
was used to compare controls and ESRD patients. Theemia), the FDR (FDR as the ratio B/A), and the time
gender (1 male and 2 female) and previous antihyperten-to FDR (time required for B 5 A). All measurements
sive drug therapy (1 no and 2 yes) were used as a dummywere made with a wrist cuff inflated 20 mm Hg above
variables. Univariate and multiple stepwise regressionthe SBP. Forearm vascular resistance (FVR) was calcu-
analyses were conducted to assess the relationships be-lated as MBP/FBF and was expressed in arbitrary units.
tween different parameters. All tests were two sided,
Laboratory methods and the P value , 0.05 was considered significant.
Arteriovenous fistula blood was obtained immediately
before hemodynamic investigations after an overnight
RESULTSfast. The plasma was separated without delay at 48C in a
Study populationrefrigerated centrifuge and stored at 2208C until plasma
determinations were performed. Routine biochemical The two groups were similar in terms of age, sex ratio,
parameters were determined using standard methods, SBP, and DBP. ESRD patients were significantly shorter,
and serum albumin, plasma fibrinogen, and C-reactive weighed less, and had a shorter heart period (R-R inter-
protein (CRP) were measured nephelometrically. Total val; Table 1). ESRD patients had significantly higher LV
mass, CCA diameter and IMT, and lower CCA distensi-plasma homocysteine was determined with the fluoro-
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Table 3. Blood chemistry parametersTable 1. Clinical characteristics
Controls ESRD Controls ESRD
Parameters (N 5 34) (N 5 60)Parameters (N 5 34) (N 5 60)
Age years 50610 54614 Hemoglobin g/dL 14.961.6 11.161.9c
Glucose mmol/L 5.0260.48 4.8460.56Gender M/F ratio 1.3 1.3
Height cm 171611 166610a Total cholesterol mmol/L 5.2861.04 4.9161.06
HDL cholesterol mmol/L 1.3860.39 1.0960.38bWeight kg 77615 65612a
SBP mm Hg 146619 148629 Triglycerides mmol/L 1.3960.63 1.8760.96b
Serum albumin g/L 4461 3963cDBP mm Hg 85614 82613
MBP mm Hg 106615 105617 Fibrinogen g/L 3.2160.78 4.7561.04c
Smoking status pack /years 10.5617.6 11.0617.3Pulse pressure mm Hg 61615 66623
R-R interval ms 1007631 8606133a Plasma homocysteine lmol/L 8.861.2 36614c
vWF % 9666 142630cValues are means 6 standard deviation. Abbreviations are in the Appendix.
PAI-1 lg/L 1067 17625aaP , 0.001
CRP mg/L 3.561.0 11.7614.9c
PTH pg/L 2867 3146270c
Values are means 6 standard deviation. Abbreviations are: vWF, von Wille-
brand factor; PAI-1, plasminogen activator inhibitor-1; CRP, C-reactive protein;
PTH, parathormone.Table 2. Cardiac and arterial measurements
aP , 0.05
bP , 0.01Controls ESRD
cP , 0.001Parameters (N 5 34) (N 5 60)
Cardiac
LV mass g 204667 270684c
LV mass index g/m2 107628 156647c
Table 4. Simple correlations between flow debt repayment (FDR)Cardiac output mL/min/100 g 5.3361.80 7.4261.90c
or age and various analyzed parametersCarotid
CCA diameter mm 5.760.7 6.461.0c Parameters FDR Age
CCA IMT lm 738696 7926103b
Age years 20.575c 20.575cCCA distensibility kPa21 · 1023 20.667.2 16.868.4a
Dialysis month 20.261a 20.387bPeripheral
SBP mm Hg 20.354b 0.254aBaseline FBF mL/100 mL/min 3.5061.30 3.9561.30
Antihypertensive drugs (1, yes; 2, no) 20.020 20.274aBaseline FBF/cardiac output ratio 0.7060.31 0.5660.22a
CCA diameter mm 20.580c 0.657cBaseline FVR arbitrary units 34.1614.7 29.6631.2
CCA IMT lm 20.470c 0.390bPeak FBF mL/100 mL/min 29.269.1 27.9610.2
CCA distensibility kPa21 · 1023 0.550c 20.691cPeak FBF % of baseline 8526340 7226309a
Smoking status pack /years 20.030 0.129Peak FVR arbitrary units 4.361.7 4.862.6
Hemoglobin g/dL 0.201 0.033FDR % 116631 88632c
Serum albumin g/L 0.550b 20.285aDuration of hyperemia s 127636 96632c
Total cholesterol mmol/L 20.090 0.190Time to FDR s 110654 162672c
Plasma homocysteine lmol/L 20.061 20.303a
Values are means 6 standard deviation. Abbreviations are: LV, left ventricu- vWF % 20.501c 0.403clar; CCA, common carotid artery; IMT, intima-media thickness; FBF, forearm
PAI-1 lg/L 20.550c 0.249blood flow; FBR, forearm vascular resistances; FDR, flow debt repayment.
Fibrinogen g/L 20.254a 0.240aP , 0.05
CRP mg/L 20.230 0.213bP , 0.01
cP , 0.001 PTH pg/L 20.136 20.180
Abbreviations are: CCA, common carotid artery; IMT, intima-media thick-
ness; vWF, von Willebrand factor; PAI-1, plasminogen activator inhibitor-1;
CRP, C-reactive protein; PTH, parathormone.
aP , 0.05
bP , 0.01bility (Table 2). While their CO values were higher, their
cP , 0.001
baseline FBF and FVR were not significantly increased,
and their FBF/CO ratio was lower (P , 0.05). In addi-
tion, their absolute values of peak postischemic FBF and
FVR did not differ significantly from those in controls. also interacted among themselves. Table 4 shows the
simple correlations between FDR or age and variousIn ESRD patients, the FDR was lower because of the
shorter duration of the hyperemic response, and their studied parameters. Moreover, many biochemical pa-
rameters were also mutually correlated, like the negativetime to total postischemic FDR was longer (Table 2).
Blood chemistry for the two study populations differed correlations between serum albumin and CRP and/or
fibrinogen (P , 0.01). Therefore, all studies analyzing thesignificantly (Table 3), with ESRD patients having lower
high-density lipoprotein cholesterol and serum albumin, correlations between arterial parameters, postischemic
flow alterations, and blood biochemistries were analyzedand higher triglycerides, fibrinogen, CRP, plasma homo-
cysteine, vWF, PAI-1, and PTH levels. by multiple stepwise regression after adjustment for age,
BP, and confounding variables. Only those correlationsRelationships between cardiovascular parameters, post-
ischemic vasodilation, and blood chemistry. Many of the significant after these adjustments were analyzed and
presented.studied parameters were correlated with age and BP but
Pannier et al: Endothelium and cardiovascular remodeling in uremia 1095
Table 5. Multiple correlation analyzes between flow debt repayment (FDR) and dependent parameters in the entire ESRD
population and those patients with PAI-1 determination
Dependent variable
Independent variable: FDR b-coeff t-value P Sequential r 2 Partial r 2
Entire ESRD population
CCA diameter mm 214.4 25.10 0.0000 0.326 0.338
Albumin g/L 4.60 4.40 0.0001 0.525 0.275
Dialysis month 20.13 2.70 0.001 0.584 0.124
F ratio 5 23.9 (P 5 0.0000) Adjusted r 2 5 0.559
ESRD patients with PAI-1 determinations
CCA diameter mm 214.5 24.76 0.0000 0.281 0.415
Dialysis month 20.16 23.12 0.0038 0.480 0.233
PAI-1 lg/L 28.65 23.09 0.0041 0.618 0.230
Albumin g/L 3.20 2.85 0.0075 0.696 0.203
F ratio 5 18.3 (P 5 0.0000) Adjusted r 2 5 0.658
Abbreviations are: CCA, common carotid artery; PAI-1, plasminogen activator inhibitor-1.
Fig. 2. Correlation for end-stage renal dis-
ease (ESRD) patients between FDR and com-
mon carotid artery (CCA) diameter (A, r 5
0.58; P , 0.001) and CCA intima-media thick-
ness (B; r 5 0.47; P , 0.001).
Fig. 3. Correlation for ESRD patients be-
tween FDR and PAI-1 levels (A; r 5 0.55;
P , 0.001) or serum albumin (B; r 5 0.55;
P , 0.001).
In the overall population of ESRD patients, the FDR to FDR (P , 0.001). A positive correlation was observed
between LV mass and mass index and time to FDR (P ,was negatively correlated with CCA diameter and dura-
tion of dialysis and positively with the serum albumin 0.01; Fig. 4). CCA distensibility was positively correlated
with FDR (P , 0.001) and negatively with time to FDRlevel. For the ESRD patients with PAI-1 determinations,
the FDR was correlated with four parameters: CCA (P , 0.001; Fig. 5). The PAI-1 concentration was posi-
tively correlated with CCA IMT (P , 0.01) and nega-diameter, duration of dialysis, PAI-1 concentration, and
serum albumin level (Table 5). A similar relationship tively with CCA distensibility (P , 0.005; Fig. 6). The
univariate negative correlations between FDR and/orwas observed for FDR that was negatively correlated
with CCA IMT (Figs. 2 and 3) and positively with time time to FDR with age and/or BP were not significant
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the forearm contralateral to the arteriovenous fistula is
characterized by shorter duration of postischemic vasodi-
lation and a longer time to postischemic FDR, whereas
the maximal vasodilatory response does not differ from
that in control subjects.
Myogenic, neural, and local factors, such as adenosine,
prostaglandins, and/or ischemic metabolites, play critical
roles in the reactive hyperemic response because of the
transient interruption of blood supply. However, recent
studies indicate that the vascular endothelium plays a
major role in determining reactive hyperemia in both
the large and small forearm arteries. In normal subjects,
the effects of NG-monomethyl-l arginine, an inhibitor of
nitric oxide (NO) synthase, attenuates the late phase
and peak of reactive hyperemia [22, 23]. Joannides et al
demonstrated that postischemic dilation of forearm large
arteries is mainly the result of NO release by endothelialFig. 4. Scatterplot of data from ESRD patients showing the correlation
between LV mass index and time to FDR (r 5 0.35; P , 0.01). cells [24]. The same authors showed that in ESRD pa-
tients, the postischemic dilation of the radial artery is
almost abolished, with blood flow increasing only as a
secondary effect of increasing blood velocity and not
after adjustment for CCA diameter, duration of dialysis, arterial diameter [9]. Since direct vasodilation with nitro-
PAI-1 concentrations, and the serum albumin level. The prusside induced a similar response in ESRD patients
postischemic vasodilatory response was not influenced and controls, the authors concluded that uremic patients
by previous antihypertensive therapy. have defective NO-mediated endothelial function. While
the response of large conduit arteries to ischemia is prin-
cipally mediated by increased arterial diameter and flowDISCUSSION
velocity, the adjustment of the microcirculation to ische-The salient finding of the present study was that ESRD
mia is mediated by vasodilation and recruitment of newpatients exhibited significant alterations of microcircula-
microvessels. Structural changes in the microvasculature,tory adjustment to ischemic stimuli, characterized by
like reduced density or increased tortuousness of capil-
decreased postischemic FDR. This alteration was not
laries, were described in patients on hemodialysis [25, 26],
related to the difference in the postischemic peak flow, and decreased FDR could be due to altered endothelium-
but to a shorter duration of postischemic vasodilation. dependent vasodilation or decreased microvascular den-
These modifications of postischemic blood flow recovery sity and/or abnormal vessel recruitment. An argument
were significantly associated with the duration of hemo- for the latter mechanism could be the relative ischemia
dialysis treatment and some biological markers of endo- at baseline that is characterized by a lower FBF/CO ratio
thelial activation, and also with significant changes of in ESRD patients. However, several arguments go against
the structure and function of the cardiovascular system an abnormal recruitment. The principal argument is that
characterized by dilation, hypertrophy, and stiffening of at peak flow, the FBF and FVR are similar in controls
large capacity arteries. Furthermore, a significant associ- and ESRD patients. Moreover, the principal alteration
ation between LV hypertrophy and abnormal postische- observed is not a difference in peak flow, but a shorter
mic blood flow recovery was also observed in ESRD duration of hyperemia. This rapid exhaustion of the hy-
patients. peremic response is more in line with abnormal endo-
Remodeling of large arteries in ESRD patients is, in thelial function with decreased NO production and bio-
part, associated with hyperkinetic circulation and in- availability [27]. The endothelial dysfunction in ESRD
creased CO. In these patients, the hemodynamic effects patients was also suggested by increased plasma levels
of increased blood flow on the cardiac and macrocircula- of vWF and PAI-1 and other factors [28, 29]. The endo-
tion have been widely reported, whereas alterations of thelial dysfunction could be due to chronic “activation”
the microcirculation have been less extensively studied. of the endothelium resulting from chronically increased
The microcirculation is indeed altered in ESRD patients, hemodynamic stress [30, 31], chronic proinflammatory
as shown by decreased forearm musculocutaneous vaso- conditions and oxidative stress [32] or accumulation of
dilator response to various stimuli including ischemia endogenous inhibitors of the l-arginine/NO pathway
[9, 10, 12, 13], hyperthermia [11], or acetylcholine [14]. [33]. The present study showed increased blood levels of
several markers of endothelial activation and significantThe present data indicate that at rest, the circulation in
Pannier et al: Endothelium and cardiovascular remodeling in uremia 1097
Fig. 5. Correlation of data from ESRD pa-
tients between FDR (A; r 5 0.55; P , 0.001)
or time to FDR (B; r 5 0.50; P , 0.001) and
CCA distensibility.
to increased arterial stiffness and early wave reflections
[2, 3, 6]. In the present study, we observed an association
of reactive forearm hyperemia with LV hypertrophy and
remodeling of large arteries, indicating that in ESRD,
arteriosclerosis of large vessels is accompanied and paral-
leled by alterations of the microcirculation, that is, by
downstream dysregulation [35]. Moreover, a significant
correlation was observed between the response to ische-
mia and stiffening of large arteries. The endothelium
plays a pivotal role in the process of vascular remodeling
[7, 8], and experimental studies have shown that NO
synthase activity is linked to end-organ damage such as
cardiac or aortic hypertrophy [36, 37]. An impairment
of NO synthase activity is more commonly seen in salt-
sensitive hypertension [38, 39], which is a common fea-
ture in ESRD patients. Finally, interactions between re-
Fig. 6. Scatterplot showing the correlation for ESRD patients between duced endothelium-dependent forearm vasodilation and
CCA distensibility and PAI-1 concentration (r 5 0.34; P,0.005). LV hypertrophy and carotid wall thickening were also
observed in patients with essential hypertension [40].
The role of endothelial alterations in cardiovascular re-
modeling in ESRD patients was suggested by the resultscorrelations between the reduced reactive hyperemic re-
of an earlier study, which indicated the existence of sig-sponse and the circulating levels of these markers, sug-
nificant correlations between LV mass and CCA IMTgesting that the decreased postischemic vasodilation ob-
and the plasma endothelin level and between endothelinserved in ESRD patients results from altered endothelial
levels and decreased postischemic vasodilation [12]. Thefunction. This interpretation is limited by several factors,
participation of endothelial activation in the process ofthe most important being the poor specificity of these
vascular remodeling was also suggested in the presentendothelial markers. In pathological states, these mark-
study by the relationship between the altered FDR anders are not endothelium specific and could be released
CCA distensibility or PAI-1 concentrations. Elevatedby platelet activation or could be the expression of acute-
circulating concentrations of PAI-1 reflect reduced fi-phase reaction and inflammation [34], conditions fre-
brinolytic activity. Reduced fibrinolysis may predisposequently observed in uremia.
to macrovascular and microvascular disease, and highThe heart and the vascular system are two functional
plasma PAI-1 activity is a risk factor for coronary arteryunits joined together to form a coupled biological system.
disease, acute recurrent myocardial infarction, and reste-Previous studies showed that in ESRD and essential
nosis after angioplasty [41, 42].hypertensive patients, cardiac remodeling was closely
In ESRD patients, hypoalbuminemia is associatedparalleled by remodeling of the arterial system [3]. In
with LV dilation [43] and the presence of atheromatousESRD patients, the cardiovascular remodeling is in part
plaques [44]. In the present study, the decreased serumdue to volume and pressure overload. Volume overload
albumin level was an independent factor associated withis principally due to anemia, overhydration, and arterio-
venous shunts, whereas pressure overload is mainly due lower FDR in ESRD patients. Hypoalbuminemia may
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vessel wall properties in hemodialysis patients. Kidney Int 45:1397–affect blood viscosity or endothelial function as a conse-
1400, 1994
quence of increased concentrations of free lysophospha- 5. Lindner A, Charra B, Sherrard D, Scribner BM: Accelerated
atherosclerosis in prolonged maintenance hemodialysis. N Engl Jtidylcholine that alters erythrocyte structure [45] or may
Med 290:697–702, 1974inhibit NO-mediated vascular relaxation [46–48]. Hyper-
6. London GM, Dru¨eke TB: Atherosclerosis and arteriosclerosis in
homocysteinemia can be toxic to the vascular endothe- chronic renal failure. Kidney Int 51:1678–1695, 1997
7. Gibbons GH, Dzau VJ: The emerging concept of vascular remod-lium by promoting oxidative damage [49], and plasma
eling. N Engl J Med 330:1431–1438, 1994homocysteine concentrations are elevated in ESRD pa-
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66:321–328, 1988levels were associated with neither cardiovascular remod-
9. Joannides R, Bakkali EH, Le Roy F, Rivault O, Godin M,
eling nor with reactive hyperemia. We did not observe Moore N, Fillastre J-P, Thuilliez CH: Altered flow-dependent
vasodilatation of conduit arteries in maintenance haemodialysis.any relationship between the arterial geometry or postis-
Nephrol Dial Transplant 12:2623–2628, 1997chemic vasodilation and lipid abnormalities or increased
10. Bradley JR, Evans DB, Cowley AJ: Abnormalities in the periph-
PTH in ESRD patients. Nevertheless, the present obser- eral circulation in patients with chronic renal failure. Nephrol Dial
Transplant 3:412–416, 1988vations have some limitations due principally to their
11. Wilkinson SP, Spence VA, Stewart WK: Arterial stiffening andcross-sectional and observational nature, and interven-
reduced cutaneous hyperaemic response in patients with end-stage
tional studies are necessary to delineate the precise roles renal failure. Nephron 52:149–153, 1989
12. Demuth K, Blacher J, Gue´rin AP, Benoit M-O, Moatti N, Safarof various factors implicated in the altered endothelial
ME, London GM: Endothelin and cardiovascular remodelling inand cardiovascular functions in uremic patients.
end-stage renal disease. Nephrol Dial Transplant 13:375–383, 1998
In conclusion, the results of the present study demon- 13. van Guldener C, Janssen MJF, Lambert J, Steyn M, Donker
AJN, Stehouwer CDA: Endothelium-dependent vasodilatation isstrated that forearm-reactive hyperemia, a parameter
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